All In Biotech

Drug Trial Radar · NCT06309823

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

Last checked: Nov 19, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1

Actual

Start

Feb 8, 2023

Primary completion

Jan 17, 2024

Study completion Jan 17, 2024

Sponsor

Lead sponsor
The Hospital for Sick ChildrenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 13 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1 beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2. Clinical trials are currently examining its efficacy in other diseases associated with elevations of these cytokines, including NLRC4-associated disease and hidradenitis suppurativa. This study proposes to assess the effectiveness of MAS825 in a single patient with XLP-2, who has previously demonstrated response to blockade of IL-1 beta and IL-18. Given the lack of alternative pharmaceutical options for XLP-2, this represents the only known medication option that avoids the toxicity associated with high-dose corticosteroids and the morbidity associated with hematopoietic stem cell transplantation.

Conditions

  • X-linked Lymphoproliferative Syndrome Type 2 (XLP-2)

Interventions

  • MAS825Drug

    MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Impact of MAS825 on Physician Global Assessment ScoreTime frame: 5 years
  2. Impact of MAS825 on Physician Severity Assessment of Disease Signs and SymptomsTime frame: 5 years
  3. Patient/Parent Global Assessment of Disease ActivityTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.